抗連環(huán)蛋白β1(β-catenin)多克隆抗體
Anti-Beta Catenin (β-catenin) Polyclonal Antibody
CTNNb1; bCat; b-Cat; CTNN-B1; Catenin Beta 1; Cadherin-Associated Protein
- 編號(hào)CAB021Mi01
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種Homo sapiens (Human，人), Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠), Oryctolagus cuniculus (Rabbit，兔), Felis catus; Feline (Cat，貓), Canis familiaris; Canine (Dog，犬), Sus scrofa; Porcine (Pig，豬), Bos taurus; Bovine (Cattle，牛), Capra hircus; Caprine (Goat，山羊), Equus caballus; Equine (Horse，馬), Chicken (Gallus，雞), Xenopus (Clawed frog，非洲爪蟾)
- 應(yīng)用Loading Control of WB.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 644 ¥ 1504 ¥ 2148 ¥ 5370 ¥ 21480
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. Western Blot; Sample: Recombinant CTNNb1, Human.
-
Figure Western Blot
Lane1: Human Lung Tissue
Lane2: Mouse Liver Tissue
Lane1: Mouse Lung Tissue
Primary Ab: 1:500 ?Dilution?of?Rabbit Anti-Human CTNNb1 Ab
Second Ab: 1:2000?Dilution?of?HRP-Linked?Guinea?pig?
Anti-Rabbit Ab (Catalog: SAA544Rb59)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)β-catenin的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別β-catenin。
用法
Western blotting:1:500-2000
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| CAB021Mi01 | 抗連環(huán)蛋白β1(β-catenin)多克隆抗體 | Loading Control of WB. |
| CAB021Mi22 | 抗連環(huán)蛋白β1(β-catenin)單克隆抗體 | Loading Control of WB |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinica Chimica Acta | Versican and its associated molecules: Potential diagnostic markers for multiple myeloma [Pubmed:25623955] |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth [Pubmed:25639729] |
| Am J Transl Res | Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats [PubMed: 26396666] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
| Life Sciences | Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. [pubmed:28754618] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
| The Showa University Journal of Medical Sciences | Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/β-catenin Signaling Pathway in Triple-negative Breast Cancer [Doi: 10.15369/sujms.30.359] |
| Advances in?Medical?Sciences | Urinary procollagen III aminoterminal propeptide and β-catenin–New diagnostic biomarkers in solitary functioning kidney? [Pubmed: 30738287] |
| Biomed Pharmacother | Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway [Pubmed: 32028241] |
| Journal of Cosmetic Dermatology | Novel complex of cosmetic ingredients with promising action in preventing hair loss and follicular aging through mechanism involving enrichment of WNT/signaling?… [Pubmed: 33179848] |
| Nutrients | Hydroxytyrosol as a Promising Ally in the Treatment of Fibromyalgia [Pubmed: 32784915] |
| Oncotarget | Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme [33473259] |
| Cytokine | QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model [34564023] |
